NCT03241745已完成2 期
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 8
- 主要终点
- Progression-Free Survival
研究概览
简要总结
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of metastatic or recurrent uterine cancer (endometrial carcinoma, carcinosarcoma, clear cell carcinoma, leiomyosarcoma, undifferentiated sarcoma, high grade endometrial stromal sarcoma) by Memorial Sloan Kettering Cancer Center. Carcinosarcomas, endometrioid and clear cell carcinomas that appears to have arisen in the ovary/fallopian tube or peritoneum are also eligible. Recurrence should not be amenable to curative approaches such as surgical resection or chemoradiotherapy.
- •Tumor is confirmed to be one of the following:
- •MSI-high, or
- •MMR-deficient, or
- •Hypermutated defined as ≥20 somatic mutations in the tumor by MSK-IMPACT
- •One or more prior lines of cytotoxic treatment for advanced disease (prior hormonal therapy is not considered to count as prior lines of therapy)
- •Measurable disease by RECIST 1.1 criteria
- •No known CNS metastases
- •ECOG Performance status 0-1
- •ECOG Performance status 0-1
- •WBC ≥ 2000/uL, ANC ≥ 1500/uL, PLT ≥ 100,000/uL, HGB ≥ 8 g/dL
- •Serum creatinine ≤ 1.5 x ULN or creatinine clearance of ≥ 40mL/min by Cockroft-Gault formula
- •AST (SGOT) and ALT (SGPT) ≤ 3 x ULN
- •Total bilirubin ≤ 1.5 x ULN, except subjects with Gilbert's syndrome who can have total bilirubin ≤ 3.0 mg/dL
- •Able to sign voluntary written informed consent
- •Female, 18 years of age or older
- •Available archival tumor tissue or patient is willing to undergo new biopsy
- •Premenopausal women of child bearing potential must have a normal urine or serum beta-HCG prior to enrollment, and must agree to use effective contraception during treatment with nivolumab and for at least 5 months following the last dose of nivolumab.
排除标准
- •Disease eligible for potentially curative treatment with standard chemotherapy, surgical resection, or chemoradiotherapy.
- •Known or suspected autoimmune disease, except for subjects with vitiligo, diabetes mellitus, resolved childhood asthma/atopy, residual hypothyroidism due to an autoimmune immune condition only requiring thyroid hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
- •Serious uncontrolled medical disorder or active infection which would impair the ability of the subject to receive protocol therapy or whose control would be jeopardized by protocol therapy
- •History of bowel obstruction, refractory ascites, or bowel perforation due to advanced disease within the past 3 months from start of study treatment.
- •Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways
- •Patients who have a condition that requires systemic treatment with either corticosteroids within 7 days of enrollment (systemic corticosteroid therapy is defined as >10 mg daily prednisone or its equivalent); or who require other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Prior history of malignancy or a concurrent malignancy, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, or in situ carcinoma of the uterine cervix, prostate, or breast, unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated to be required during the study period
- •Breastfeeding women, pregnant women
- •Prisoners or subjects who are involuntarily incarcerated
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
- •Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (if patient has documented Hepatitis B and C from within 6 months of enrollment, these tests do not need to be repeated.)
- •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •Known allergy or Adverse Drug Reaction to nivolumab, or a history of allergy to study drug components.
研究组 & 干预措施
Nivolumab
Experimental
Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
干预措施: Nivolumab (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: at 24 weeks
will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesVarious Advanced CancerNCT03130959Bristol-Myers Squibb166
已完成
2 期
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadMicrosatellite Unstable Colorectal CancerMicrosatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal CancerMismatch Repair Deficient Colorectal CancerNCT02060188Bristol-Myers Squibb385
已完成
2 期
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerMicrosatellite Stable (MSS) Colorectal AdenocarcinomasColorectal AdenocarcinomaNCT03642067Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins59
进行中（未招募）
2 期
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)Thymoma Type B3Thymic CarcinomaNCT03134118European Organisation for Research and Treatment of Cancer - EORTC55
进行中（未招募）
1 期
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaOsteosarcomaOsteosarcoma in ChildrenOsteosarcoma RecurrentSarcomaNCT03628209H. Lee Moffitt Cancer Center and Research Institute21